Figure 3 Genetic pleiotropy in ALS

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Three Families With Amyotrophic Lateral Sclerosis.

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Life expectancy at birth in all countries included

MRI and possible differentiating features with nonconventional MRI

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 2 Grey matter atrophy in FTD

Figure 2 Flow chart of patients who met the inclusion/exclusion criteria for the study Flow chart of patients who met the inclusion/exclusion criteria.

Figure 3 Translational research projects in LGMD

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Figure 2 Examples of lesions with and without central veins

Figure 1 Evolution of multiple sclerosis

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Translocations involved in multiple myeloma

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Nat. Rev. Neurol. doi: /nrneurol

the SNP profile using 26 prostate cancer GWAS risk SNPs

Figure 3 Transcripts of the splicing mutation (c

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Cellular pathways implicated in CIPN

Figure 3 Temporal trends in FALS incidence

Nat. Rev. Neurol. doi: /nrneurol

Diversity of methods utilized to model neurological diseases using patient‐derived iPSCs Diversity of methods utilized to model neurological diseases using.

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Percentage distribution according to severity of baseline behavioral changes in behavioral variant frontotemporal dementia (bvFTD) and semantic.

Figure 2 Network connections of the hypothalamus

Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and.

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Figure 3 Genetic pleiotropy in ALS Figure 3 | Genetic pleiotropy in ALS. Several genetic variants associated with amyotrophic lateral sclerosis (ALS) are also associated with frontotemporal dementia (FTD). In this stalagmite plot, the size of each plotted point is in direct proportion to the number of publications on ALS and FTD that reference the gene specified. The position on the x-axis corresponds to the proportion of publications in ALS and FTD. Al-Chalabi, A. et al. (2016) Gene discovery in amyotrophic lateral sclerosis: implications for clinical management Nat. Rev. Neurol. doi:10.1038/nrneurol.2016.182